Implementing cross-border transfer of domestic plasma to obtain plasma-derived medicinal products: policy guidance

Overview

The document provides recommendations on legal, regulatory and policy conditions for assuring the quality of plasma for fractionation and protecting the health of plasma donors. It also discusses alternative arrangements for foreign fractionation of domestic plasma (termed “contract” or “toll” fractionation), which realize the medical and economic value of the plasma as a national resource for public health.